Abstract
This study analyzes clinical data from 514 pediatric patients in Shenzhen, China, to evaluate the impact of the SARS-CoV-2 Omicron subvariant BA.2. Results indicate that BA.2 is highly infectious with a median incubation period of one day. However, inactivated vaccines significantly reduce symptom severity, lower fever duration, and accelerate viral clearance, particularly after two doses.
Introduction
The emergence of the Omicron BA.2 subvariant in early 2022 led to a noticeable increase in pediatric hospitalizations globally. While Omicron was recognized for its high transmissibility and ability to evade vaccine-induced immunity, specific clinical data regarding BA.2 in children was initially limited. This research addresses critical questions regarding the severity, clinical presentation, and effectiveness of inactivated vaccines—widely used in regions like China—against this specific subvariant in a pediatric setting.
Methods
Researchers conducted a retrospective study of 514 pediatric patients (aged ≤14 years) admitted to Shenzhen Third People’s Hospital between January 2020 and March 2022. The study compared clinical outcomes across different variants, including BA.2 (465 cases), Wild-type (41 cases), and Delta (8 cases). The analysis focused on vaccination status (unvaccinated vs. one or two doses of inactivated vaccines), viral kinetics measured via Cycle threshold (Ct) values from RT-PCR tests, and serological responses (IgM and IgG antibody levels).
Key Insights
A primary finding of the study is the remarkably short median incubation period for BA.2 in children, which was found to be just one day. This rapid onset explains the high rate of familial clustering observed, with 84.1% of infected children belonging to clusters with multiple infected family members.
Furthermore, the clinical presentation of BA.2 in children shifted towards upper respiratory symptoms. While fever (58.9%) and sore throat (30.0%) were common, children were significantly less likely to develop pneumonia compared to those infected with earlier strains.
Key Results
The study demonstrates a significant "step-up" in protection provided by the second vaccine dose. Children who received two doses of inactivated vaccines exhibited substantially higher IgG antibody levels compared to those with only one dose or no vaccination.
Vaccination was associated with improved clinical outcomes, including lower rates of fever (45.7% vs. 71.9%) and a shorter average fever duration (1.75 days vs. 2.53 days). Additionally, vaccinated children achieved viral clearance significantly faster, with an average time to a negative PCR test of 9.3 days compared to 11.2 days for unvaccinated children. A clear negative correlation (R = -0.28) was identified between IgG antibody levels at admission and the time required for nucleic acid negative conversion.
Discussion and Limitations
While Omicron BA.2 is highly transmissible among children, inactivated vaccines remain a potent tool for mitigating disease severity and accelerating recovery. The data underscores the importance of completing the two-dose vaccination schedule and suggests that booster shots may be necessary as antibody levels wane over time.
Limitations of the study include the small sample size for the Delta variant comparison group and the focus on inactivated vaccines, which may limit direct applicability to mRNA vaccine cohorts. As a retrospective hospital-based study, there is also a potential for selection bias regarding the severity of cases analyzed.
Summary updated